tj210001
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 17, 2020 (NCT04678921)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
C5AR1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04947033 | Phase 1 | Dec 31, 2021 | Huazhong University of Science and Technology, I-Mab Biopharma |
| NCT04678921 | Phase 1 | Dec 17, 2020 | I-Mab Biopharma |
| NCT05511350 | N/A | — | Horizon Oncology Center, I-Mab Biopharma |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| I-Mab Biopharma | For profit | 3 | 3 | 2 | 2020 |
| Horizon Oncology Center | Academic/Hospital | 1 | 0 | 1 | — |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1